KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Short term Debt: 2018-2021

Historic Short term Debt for Twist Bioscience (TWST) over the last 3 years, with Dec 2021 value amounting to $9.1 million.

  • Twist Bioscience's Short term Debt rose 172.49% to $9.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $9.1 million, marking a year-over-year increase of 172.49%. This contributed to the annual value of $1.6 million for FY2021, which is 53.44% down from last year.
  • Twist Bioscience's Short term Debt amounted to $9.1 million in Q4 2021, which was up 485.18% from $1.6 million recorded in Q3 2021.
  • Twist Bioscience's Short term Debt's 5-year high stood at $9.1 million during Q4 2021, with a 5-year trough of $1.6 million in Q3 2021.
  • Its 3-year average for Short term Debt is $3.6 million, with a median of $3.3 million in 2020.
  • Over the last 5 years, Twist Bioscience's Short term Debt had its largest YoY gain of 172.49% in 2021, and its largest YoY loss of 53.44% in 2021.
  • Twist Bioscience's Short term Debt (Quarterly) stood at $3.3 million in 2018, then remained steady at $3.3 million in 2019, then remained steady at $3.3 million in 2020, then skyrocketed by 172.49% to $9.1 million in 2021.
  • Its Short term Debt stands at $9.1 million for Q4 2021, versus $1.6 million for Q3 2021 and $2.4 million for Q2 2021.